NCT00875745 - Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

May 31, 2010

Study Completion Date

October 31, 2013

Conditions

Leukemia, Myeloid, AcuteLeukemia, Promyelocytic, AcuteMyelodysplastic Syndromes

Interventions

DRUG

Sorafenib-Vorinostat

Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis